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Abstract: Ebola virus disease (EVD) was defined first in 1976. Since then, more than 24 epidemics have been reported from Africa,
predominantly with the Zaire species. On 21 March 2014, the current West Africa outbreak was reported by the World Health
Organization, the largest one ever recorded. The Congo epidemic was reported in July 2014. It was considered that the two epidemics
had unrelated origins with 96.8% identical genomic sequence of the virus. EVD outbreaks occurred in areas with limited resources but
it has a potentially global effect due to the possibility of imported infection and the potential misuse of the virus as a bioweapon agent.
Although EVD is a zoonotic disease with the reservoir of fruit bats, human-to-human transmission is essential in the spread of the
infection. The case-fatality rate of EVD was reported as 70.8%. There is no approved prophylaxis, effective treatment, or licensed vaccine.
Early diagnosis and isolation of the patients, contact tracing, appropriate use of personal protective equipment , and adherence to the
guidance for safe funeral practices constitute the essential requirements to control the epidemics. This article provides a review of the
literature regarding the characteristics and management of EVD outbreak.
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1. Introduction
The Ebola virus, which belongs to the viral family
Filoviridae, causes Ebola virus disease (EVD) and is
endemic to Central Africa. Fruit bats of the family
Pteropodidae are the recognized reservoir of the virus
(1,2). Five distinct species of the virus are the Zaire, Sudan,
Ivory Coast, Bundibugyo, and Reston agents, which are all
limited to Sub-Saharan Africa (except the Reston virus,
which was defined in the Philippines and has not caused
any symptomatic disease in humans) (3,4). The Ebola virus
is an important threat to the world due to the possibility of
misuse as a biological weapon and imported infections as
a result of increased international travelers (5). There have
been 25 outbreaks reported to date including the current
outbreak: four in 1976–1979, six in 1994–1996, nine in
2000–2008, and six after 2011 (6,7). The current outbreak
involves the Zaire species of the virus and is occurring
in West Africa (Guinea, Liberia, Sierra Leone, Senegal,
and Nigeria); it started in Guinea in late 2013 and was
confirmed by the World Health Organization (WHO) in
March 2014. It is the largest outbreak to date with a total
of 10,141 cases (5692 of which were confirmed) and 4922
deaths by 25 October 2014 (4,8). Twenty-seven of them
were reported as travel-associated cases and localized
transmissions: 20 cases from Nigeria, 4 from the United
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States, and one each from Senegal, Mali, and Spain. The
outbreaks of EVD in Senegal and Nigeria were announced
on 17 and 19 October 2014, respectively. A national
EVD outbreak is considered to be over when double the
maximum incubation period (42 days) has passed after the
last patient became laboratory-negative for EVD (8). On
26 July 2014, another EVD epidemic was reported from
the Congo in Equatorial Africa, which had a zoonotic
origin different from the current epidemic in West Africa.
By 21 October 2014, there had been 67 cases of EVD (38
laboratory-confirmed cases and 49 deaths) reported in the
Democratic Republic of the Congo. When the genome
sequence of the virus was analyzed, it was observed that
it shared 96.8% identity with the current West Africa
Ebola virus variant and 99.2% identity with the variants
of the 1995 outbreak in the Congo (7,9). The case-fatality
rate of EVD is very high, ranging between 20% and 90%
depending on the virus species (1,2). The highest mortality
rate (60%–90%) is seen with the Zaire Ebola virus species,
followed by the Sudan Ebola virus species (40%–60%).
The Bundibugyo virus species has caused only one
outbreak to date, with a 25% mortality rate. Case-fatality
rate was reported as 70.8% in the current outbreak when
the first 9 months of data were evaluated (10). Systemic
inflammatory response syndrome is a characteristic of
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EVD, which causes vascular impairment, disseminated
intravascular coagulopathy, and immune deficiency and
results in multiorgan failure, shock, and death in severe
cases (5). Awareness of the disease’s symptoms and
transmission routes, use of active surveillance systems,
rapid identification of cases, contact tracing, isolation
of patients, and appropriate use of personal protective
equipment (PPE) are the main factors to prevent outbreaks.
Community education is also critical (6). In this review,
we aimed to identify the clinical characteristics and patient
management of EVD in light of the literature.
2. Clinical findings
The Ebola virus causes severe hemorrhagic fever with
acute onset of nonspecific flu-like symptoms after the
incubation period (range: 2–21 days; approximately
6 days for percutaneous transmission and 10 days for
contact exposure). Fever, weakness, malaise, headache,
diarrhea, and vomiting are nonspecific symptoms that
cause misdiagnosis of the patients, such diagnoses
of typhoid fever or malaria in the early period of the
outbreak (4, ). Fever (39–40 °C) and relative bradycardia
are frequent findings seen in the early phase of the disease.
Nonpruritic maculopapular rash is usually seen between
5 and 7 days on the trunk and upper arms, ending with
desquamation in the convalescence period. Mucosal
hemorrhage (especially in the conjunctiva), petechiae,
ecchymosis, and oozing from venipuncture sites can be
observed in patients. Massive hemorrhage, typically in
the gastrointestinal system, is usually observed only in
fatal cases (11,12). Anorexia, vomiting, diarrhea, and
abdominal pain constitute the gastrointestinal system
findings (5). Scleral icterus is a rare manifestation that
was reported in the literature (11,12). According to the
reported data of the first 9 months of the current outbreak,
fever (87.1%), fatigue (76.4%), vomiting (67.6%), diarrhea
(65.6%), loss of appetite (64.5%), headache (53.4%), and
abdominal pain (44.3%) were the common symptoms in
the early phase of EVD. Unexplained bleeding was reported
in only 18.0% of cases. Mortality predictors were reported
as old age (≥45 years, OR: 2.47), hemorrhages (epistaxis,
OR: 8.02; bleeding gums, OR: 6.69; bleeding at injection
site, OR: 6.51; blood in urine, OR: 5.14), and a number
of signs and symptoms such as coma or unconsciousness
(OR: 4.59), difficulty swallowing (OR: 2.22), hiccups
(OR: 2.15), conjunctivitis (OR: 2.03), and confusion (OR:
2.00) (10). Fatal cases typically have more severe clinical
signs in the early phase of infection and death is usually
seen between days 6 and 16 due to major hemorrhages,
septic shock, and multiorgan failure (4,5). Fatal cases do
not produce specific antibodies (immunoglobulin M and
G), which can usually be detected in the first week of the
disease in survivors. Recovery of the signs and symptoms
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of survivors is typically observed around days 6 to 11
due to the effect of humoral antibodies. Survivors have
protracted convalescence (weeks to months) with the
findings of weakness, fatigue, headache, and loss of weight
and hair (5,11).
3. Laboratory findings
Leukopenia (as low as 1000 cells/µL) with lymphopenia
and granulocytosis is a typical finding of EVD, especially in
the early phases. As the illness progresses, leukocytosis can
be observed due to the increase in immature granulocytes
and atypical lymphocytes. Thrombocytopenia (50,000–
100,000 cells/µL) is the early finding of the disease.
Occurrence of elevated liver function enzymes is one of
the common findings of EVD, and the AST value is higher
than ALT. The mean level of AST is 7–12 times higher
than ALT in fatal cases and 2–4 times higher in survivors
(5,11). Renal function test scores may increase after the
first week of clinical onset, which is usually normal in
the early phase of the disease. Renal impairment is more
frequent in fatal cases (11–13). Disseminated intravascular
coagulation is usually seen in EVD patients. Increases in
partial thromboplastin time, prothrombin time, bleeding
time, and plasma D-dimer levels of patients with EVD
were reported in literature (5). D-Dimer levels of patients
with EVD in the 2000 outbreak of Sudan were reported to
be significantly higher in fatal cases (13). Increased risk
of miscarriage was reported among infected pregnant
women (5).
4. Transmission and prevention of EVD
Recent studies show that fruit bats are the reservoir for
Ebola virus species. The initial transmission to humans
may be the result of contact with bats’ or sick nonhuman
primates’ excretions in forested areas and/or consumption
of infected animals (6). The virus enters the body via
inhalation, through abrasions of the skin or mucosal
areas, or via the parenteral route. Outbreaks usually occur
as a consequence of human-to-human transmission of
the virus via contact with body fluids of symptomatic
patients and/or infected corpses (3,10,14). The estimated
reproduction number (R0), which shows the average
number of secondary cases after exposure to a primary
case in an uninfected population, was reported as 1.71 for
Guinea, 1.83 for Liberia, and 2.02 for Sierra Leone in the
first 9 months of the current epidemic. When the R0 value
of the infection is observed to be higher than 1, it means
that the spread rate of the infection will be high, which
is directly proportional to the level of R0. In addition, the
mean length of time between the onset of the symptoms
and hospitalization was reported to be 5.0 ± 4.7 days in
the current EVD epidemic, which indicates the period
of infectiousness in the community. However, since
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patients are infectious only after they have symptoms,
early diagnosis and isolation of symptomatic patients
is essential for limiting transmission in the community.
Contact tracing and follow-up surveillance of all contacts
are other critical factors to control the further spread of
the infection. The suggested time for the follow up of
contacts is 21 days, which is the maximum incubation
period (10,15). Currently, due to the increasing number
of international air travelers, contact tracing involving
passengers who traveled with an infected individual is
another important issue. Although there is no known
transmission case recorded in an aircraft for EVD to date,
it is recommended that co-travelers who have had direct
contact with the index case and/or sat adjacent to the
index case (side by side or in the immediate back/front
row) should be traced. Crew members who served the
index case and staff who cleaned the relevant section of
the plane should also be traced (16). Healthcare workers
(HCWs) constitute the other important high-risk group
for transmission and should use PPE appropriately (4). A
total of 318 EVD cases among HCWs, with 151 deaths,
were reported by September 2014 (10). Inadequacies in
hospital infrastructure, limited numbers of HCWs per
person, and absence of sufficient PPE (gloves, face masks,
gowns, etc.) are the main causes of the transmission of
EVD to HCWs in the current outbreak. Not only the
establishment of isolation units but also the provision
of sufficient PPE is necessary to reduce transmission
(17). Gloves, impermeable gowns, medical masks, eye
protection, and fluid resistant shoes, such as rubber boots,
are the suggested PPE. While applying aerosol-generating
procedures, the wearing of FFP2 or N95 respirator masks
is also suggested. In addition, training of HCWs about
the appropriate procedure of putting on and removing
PPE and applying hand hygiene is essential, as detailed in
the guidelines of the WHO (18). Reusing contaminated
medical equipment is another transmission route of
infection in healthcare settings, which should be avoided
(3). Since dead bodies are infectious, burial practices
should include the decontamination of deceased bodies
with 1:10 sodium hypochlorite solution and placement in
a plastic body bag (19). In addition to all these precautions,
education in healthcare settings and in the community
(especially how to recognize the suspected/probable cases,
symptoms, routes of transmission, and protection) is
mandatory to control epidemics (15).
5. WHO/Centers for Disease Control and Prevention
(CDC) case definitions for EVD
According to the case definitions for EVD reported by the
WHO, a suspected case was defined as follows:
1) Any ill person (alive or dead) who had high fever
with abrupt onset and had contact with a suspected/

probable or confirmed patient with EVD or contact with
a sick/dead animal.
2) Any person with abrupt onset of high fever and a
minimum of three of the following symptoms or findings:
headache, loss of appetite, anorexia, vomiting, diarrhea,
lethargy, hiccup, stomach pain, aching muscles or joints,
swallowing and/or breathing difficulties, unexplained
bleeding, or any sudden death due to an unknown cause.
A probable case was defined as any suspected patient
who had an epidemiologic link to a confirmed case in
the previous 21 days with no laboratory confirmation. A
confirmed case was defined as a suspected or probable
case with a positive reverse transcription polymerase
chain reaction (RT-PCR) test result for Ebola virus at the
reference laboratory (10,20). On 27 October 2014, the
CDC updated the case definitions to include the category
of “Person Under Investigation (PUI)” as a person who
has consistent findings or symptoms and risk factors as
follows:
1. Increased body temperature or subjective fever or
symptoms, involving fatigue, severe headache, myalgia,
vomiting, diarrhea, abdominal ache, or unexplained
bleeding; and
2. An epidemiologic risk factor within 21 days before
the initiation of symptoms.
A “Confirmed Case” is a PUI with a laboratory
confirmation of Ebola virus infection (21).
6. Diagnosis
Clinical assessment according to case definitions is
necessary for the diagnosis of EVD. Malaria and typhoid
fever are the most important infections that should
be considered in differential diagnosis, followed by
shigellosis, leptospirosis, yellow fever, and Chikungunya
fever (22). RT-PCR and antigen detection with ELISA
are the basic assays for laboratory diagnosis of acute EVD
infection, which can be positive in blood from day 3 of the
onset of symptoms until days 7–16. IgM and IgG ELISA
tests are the assays that can be used to detect specific
antibodies. IgM antibodies can be determined from day 2
after the onset of symptoms and decrease to undetectable
levels 30–168 days after infection. Specific IgG antibodies
appear after 6–18 days of the onset of the symptoms and
can be detectable for years (5,22,23). Laboratory assays
can be performed after the inactivation of the virus in the
material by different methods (heat inactivation, gamma
irradiation, denaturation of the proteins with guanidinium
isothiocyanate) (5,24,25).
7. Case management and potential therapies and vaccines
Symptomatic and supportive therapies are the basic
procedures for case management in addition to isolation of
the patient. Since it is frequently mistaken with malaria and
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other endemic infections, empiric treatment of malaria,
broad-spectrum antibiotics, analgesics, and antipyretics
should be initiated immediately while obtaining the
confirmed diagnosis. Intravenous fluid volume and
electrolyte balance should be monitored and replaced.
Complications of the disease at a later stage, such as
bleeding, renal failure, secondary bacterial infections, and
shock, are other disorders that should also be managed (5).
There are many investigations about potential therapies and
vaccines for EVD. It has been suggested that convalescent
plasma that includes antibodies of EVD survivors might
prevent the disease. However, its effect is controversial and
further investigation is necessary. Antibody treatments,
such as ZMapp and hyperimmunoglobulin, are offering
hope, but their clinical effectiveness is still not known.
Favipiravir/T-705 and interferons are other agents that have
shown effectiveness in animals but have not been studied

for Ebola in humans yet. The chimpanzee adenovirus
serotype 3 vaccine (ChAd3) and recombinant vesicular
stomatitis virus vaccine have been studied in animals and
have shown effectiveness, but there are no safety studies
in humans so far. Fifteen thousand doses of EVD vaccine
may be available by the end of 2014 according to the results
of the studies (26).
8. Conclusion
As a consequence, the current outbreak in West Africa is
not only a problem for that area but is also an important
challenge to the whole world. Since there is no available
prophylaxis, vaccine, or effective treatment for EVD, it is
necessary to break the human-to-human transmission
cycle. Education of HCWs and the broader community
about infection control precautions is essential to combat
outbreaks.
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